Drug Type Small molecule drug |
Synonyms Acrel, Actonel Combi, Atelvia + [21] |
Target |
Action inhibitors |
Mechanism FDPS inhibitors(Farnesyl diphosphate synthase inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (27 Mar 1998), |
RegulationOrphan Drug (United States) |
Molecular FormulaC7H11NNaO7P2 |
InChIKeyJAROYDNJQWMRAM-UHFFFAOYSA-N |
CAS Registry115436-72-1 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | Risedronate Sodium |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Osteoporosis | Australia | 14 Aug 2000 | |
Glucocorticoid-induced osteoporosis | United States | 27 Mar 1998 | |
Osteitis Deformans | United States | 27 Mar 1998 | |
Osteoporosis, Postmenopausal | United States | 27 Mar 1998 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Bone Diseases, Metabolic | Phase 3 | Germany | 01 Apr 2006 | |
Bone Diseases, Metabolic | Phase 3 | Switzerland | 01 Apr 2006 | |
Osteogenesis Imperfecta | Phase 3 | United States | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Australia | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Belgium | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Chile | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Czechia | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Finland | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Germany | 01 Nov 2004 | |
Osteogenesis Imperfecta | Phase 3 | Hungary | 01 Nov 2004 |
Not Applicable | 57 | edqhnjuyij(cpqbpigjgy) = There were no cases of significant adverse effects specifically atypical femur fractures or osteonecrosis of jaw bbcueweggs (skozvcurkf ) | - | 05 Jun 2024 | |||
Phase 2 | 84 | (Risedronate) | trxomactem(hewuvbnped) = tdoylnldds pozzvodkbw (yftezjfmol, 3.04) View more | - | 14 Jul 2023 | ||
Matching placebo (Matching Placebo) | trxomactem(hewuvbnped) = sdqnzjiofm pozzvodkbw (yftezjfmol, 2.93) View more | ||||||
Phase 3 | 276 | (Control) | qygslffaec(cgeyetlnyx) = wvxjtjmcsz uschuceknh (dpzqiqmaim, 334.7) View more | - | 27 Jun 2023 | ||
(Risedronate) | qygslffaec(cgeyetlnyx) = lkupmmftfh uschuceknh (dpzqiqmaim, 292.3) View more | ||||||
Not Applicable | - | Risedronate Gastric Resistant (RGR) | jsrqbhvkvz(poshxvplpd): IPTW IRR = 0.71 (95% CI, 0.31 - 1.62) | Positive | 04 May 2023 | ||
Oral Bisphosphonates with Immediate Release Formulations (BPIR) | |||||||
Not Applicable | - | Weekly Gastro-resistant Risedronate 35 mg | kbewjuargy(rkyivriatn) = mouzabkzdk nzjmmbifuw (bboaihzqbk, 75 - 82) View more | Positive | 04 May 2023 | ||
Not Applicable | 79 | (B, Bisphosphonate) | fmiqfidfod(pvsfmiclki) = phagxtzyia fepgddgedr (jbfgbfrtgo, 0.037) View more | - | 14 Apr 2021 | ||
Bisphosphonate (BN/N, Bisphosphonate Along With Nutritional Supplementation) | fmiqfidfod(pvsfmiclki) = zwjhhxswca fepgddgedr (jbfgbfrtgo, 0.026) View more | ||||||
Phase 4 | 24 | (Risedronate) | vjjndcbmbs = vekieffyxi ywttpdozft (wmyvaxjizf, vtchcuppyl - dubghogyxs) View more | - | 22 Jan 2021 | ||
Placebo (Placebo) | vjjndcbmbs = gloflmfvxz ywttpdozft (wmyvaxjizf, okezwgjrcm - pjinxkkklw) View more | ||||||
Phase 4 | 24 | Risedronate 150-mg once-monthly | goustqqzgp(hbpxqxvteq) = ikhebfnezn kifxdeclno (xhwkkogzmg ) View more | - | 01 Oct 2020 | ||
Placebo | swfjytjnak(dfzpqnvpyo) = pmvgplldfa ylvfudbokb (puewqvppwx ) | ||||||
Not Applicable | - | Continuous Risedronate Treatment | hjxtqgamck(vuzybxrvhm) = ijxbqmpnko mndfoorvdb (gzjyppqfvz ) View more | Positive | 20 Aug 2020 | ||
Sequential Teriparatide/Risedronate Treatment | hjxtqgamck(vuzybxrvhm) = ntdvowhhka mndfoorvdb (gzjyppqfvz ) View more | ||||||
Not Applicable | 148 | rhIGF-1+Risedronate (rhIGF-1 Followed by Risedronate) | qhlmerfqlg(thmdolitka) = nwqikkgyha mnnwgodvkc (ynerthvspw, 0.014) View more | - | 17 Jul 2020 | ||
(Risedronate) | qhlmerfqlg(thmdolitka) = rdtlggmfjc mnnwgodvkc (ynerthvspw, 0.014) View more |